Previous 10 | Next 10 |
home / stock / dsnky / dsnky news
Daiichi Sankyo Company Limited (DSKYF) Q4 2020 Earnings Conference Call April 27, 2021 3:00 AM ET Company Participants Sunao Manabe - President and CEO Wataru Takasaki - Head, R&D Division Hiroyuki Okuzawa - Head of Corporate Planning & Management Division and CFO Conference Call Part...
The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with their 2020 Q4 earnings call. For further details see: Daiichi Sankyo Company, Limited 2020 Q4 - Results - Earnings Call Presentation
Daiichi Sankyo Co Ltd (DSKYF) Q3 2020 Earnings Conference Call January 29, 2020 1:00 AM ET Company Participants Toshiaki Sai - EVP and CFO Wataru Takasaki - Executive Officer and Head, R&D Division Conference Call Participants Kazuaki Hashiguchi - Daiwa Securities Fumiyoshi Sakai - Credit...
The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with their 2021 Q3 earnings call. For further details see: Daiichi Sankyo Company, Limited 2021 Q3 - Results - Earnings Call Presentation
Enhertu spearheads Daiichi Sankyo's transition from a cardiovascular and metabolic drug manufacturer to an oncology player. This Japanese pharmaceutical firm can boast excellent profitability and a robust balance sheet, plus a steady dividend. The stock is overvalued by 43% at thi...
Daiichi Sankyo Co Ltd (DSKYF) Q2 2021 Earnings Conference Call November 02, 2020, 02:30 ET Company Participants Junichi Onuma - VP, Corporate Communications Department Sunao Manabe - President & Group CEO Wataru Takasaki - Executive Officer & Head, R&D Division Toshiaki Sai - CFO ...
The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with their 2020 Q2 earnings call. For further details see: Daiichi Sankyo Company, Limited 2020 Q2 - Results - Earnings Call Presentation
The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with this event. For further details see: Daiichi Sankyo (DSNKY) Presents At ESMO Follow-Up Meeting Hosted By Citi - Slideshow
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with their 2021 Q1 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Sponsored ADR Level 1 Company Name:
DSNKY Stock Symbol:
OTCMKTS Market:
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...
2023-10-31 10:15:00 ET Big pharmas have the resources to make big, multi-year moves that can reshape or even redefine their businesses. As you may know, Merck (NYSE: MRK) is one of the largest of the big pharmas, with a market capitalization of $262 billion, and it just made one of ...
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging PR Newswire TOKYO and OSAKA, Japan , Dec. 21, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO:...